Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Financing Activities (2018 - 2025)

OptimizeRx's Cash from Financing Activities history spans 12 years, with the latest figure at -$258000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 51.5% year-over-year to -$258000.0; the TTM value through Sep 2025 reached -$8.2 million, down 123.97%, while the annual FY2024 figure was -$4.9 million, 117.4% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$258000.0 at OptimizeRx, up from -$4.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $70.2 million in Q1 2021 and bottomed at -$12.0 million in Q3 2022.
  • The 5-year median for Cash from Financing Activities is -$348000.0 (2023), against an average of $3.8 million.
  • The largest annual shift saw Cash from Financing Activities surged 62476.44% in 2021 before it tumbled 3080.6% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.1 million in 2021, then tumbled by 802.65% to -$7.4 million in 2022, then surged by 586.46% to $36.2 million in 2023, then tumbled by 107.8% to -$2.8 million in 2024, then skyrocketed by 90.86% to -$258000.0 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Cash from Financing Activities are -$258000.0 (Q3 2025), -$4.5 million (Q2 2025), and -$587000.0 (Q1 2025).